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Comparison of 5-year progression of
retinitis pigmentosa involving the posterior
pole among siblings by means of SD-OCT:
a retrospective study
Leonardo Colombo1* , Giovanni Montesano1,2, Barbara Sala1, Fabio Patelli1, Paolo Maltese3, Andi Abeshi3,
Matteo Bertelli3 and Luca Rossetti1
Abstract
Background: The aim of this study is to analyze and compare the progression of photoreceptor atrophy among
siblings affected by retinitis pigmentosa by means of spectral SD-OCT.
Methods: Fifty three eyes of 27 patients belonging to 12 family clusters were analyzed. To assess the annual
progression rate of photoreceptor atrophy, the ellipsoid zone (EZ) line was measured in OCT sections through the
fovea. We used multivariate generalized mixed effects to model the rate of progression and its relation to the initial
ellipsoid zone line width.
Results: During our 4.84 years (± 1.44) mean follow up time (range 3–7) 53 eyes were examined. The ellipsoid zone
line width declined with a yearly average rate of 76.4 μm (4.16% / year) (p-value < 0.0001). Progression rates were
poorly correlated within family clusters (p-value = 0.23) and showed statistical difference between affected siblings
(p-value = 0.007). There was no correlation between inter-familiar progression rate and mode of inheritance (p-value
= 0.98) as well as between age and ellipsoid zone line width among siblings (p-value = 0.91).
Conclusion: RP could be extremely heterogeneous even among siblings: an accurate and sensitive method to
follow the progression of the disease is fundamental for future development of clinical trials and therapy strategies.
Keywords: Disease progression, Ellipsoid zone, Retinitis pigmentosa , SD-OCT, Siblings
Background
Retinitis pigmentosa (RP) is a group of inherited retinal
disorders leading to vision loss and blindness. It affects ap-
proximately 1:4000 individuals with variable modes of in-
heritance (autosomal dominant, autosomal recessive or
X-linked) [1–5].
The peculiarity of RP is its substantial heterogeneity:
more than 60 genes are involved, with many possible
disease-causing mutations on the same gene, and differ-
ent clinical outcomes may be linked to the same muta-
tion [5–11].
Despite this heterogeneity, RP patients have some com-
mon clinical features: progressive loss of photoreceptors,
typically involving the rod system. The characteristic
phenotype includes retinal bone-spicule pigmentation, pal-
lor of the optic disk and attenuation of retinal vessel [12].
No universally accepted therapies are currently avail-
able for RP but many trials are ongoing evaluating differ-
ent therapeutic approaches. Neuroprotection, stem cells,
gene therapy, optogenetics, electrical stimulation and
retinal prosthesis represent possible potential future ap-
proaches to slow down the progression of the disease or
to restore visual function in patients affected by retinal
dystrophies [13–28]. In this light, having deeper know-
ledge of the mechanisms of disease and more sensitive
methods to study its progression is becoming increas-
ingly important.
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Most of the studies evaluating RP natural course are
based on electroretinography (ERG) and visual field (VF)
data. Both methods have an important limitation in
evaluating short-term progression due to their high
test-retest variability [29–33].
Recently several studies reported the evaluation of El-
lipsoid Zone (EZ) line width at SD-OCT as sensitive and
reliable marker to detect RP progression [34–38].
The objective of our study was to evaluate disease pro-
gression among siblings affected by RP involving the
posterior pole and to test whether the progression rate
was more similar among subjects within family clusters.
For the purpose of our study we measured EZ line
changes in a 5-year mean follow up.
Methods
We retrospectively reviewed data obtained from outpa-
tients of the Retinal Dystrophies department at the Uni-
versity Eye Clinic of San Paolo Hospital in Milan.
Among the whole dataset, siblings affected by RP were
selected and, upon informed consent, recruited for the
study. Within each family siblings were followed for the
same period of time and the same number of visits.
Diagnosis of RP, clinical and OCT follow up of at least
3 years, stage of disease involving the posterior pole and
clearly measurable EZ band on OCT in all past visits
were considered as inclusion criteria.
Exclusion criteria included poor OCT scan quality
(media opacities, nystagmus), prior vitreo-retinal surgery
and not identifiable EZ band on OCT scans.
Diagnosis of RP was based on clinical signs (character-
istic bone spicule pigmentation, optic disc pallor, retinal
vessel attenuation, visual field constriction, non detect-
able scotopic electoretinographic waves) and, if available,
confirmed by results of genetic analysis. Genetic tests
were made in collaboration with MAGI Human Medical
Genetics Institute (Rovereto, Italy).
Demographic data and medical history (including the
age of diagnosis, the first symptoms onset, inheritance
model) were collected from the database. Extent of dis-
ease was considered from the date of first diagnosis.
The study was accomplished in compliance with the
Declaration of Helsinki and international guidelines.
Spectral domain optical coherence tomography (SD-OCT)
Retinal imaging was obtained using Spectralis HRA and
OCT (Heidelberg Engineering, Heidelberg, Germany).
For the study we considered single line scans of 30° and
composed of 100 averaged images using the automatic
eye tracking software horizontally across the fovea.
All patients meeting the inclusion/exclusion criteria
were re-examined. In order to compare OCT scans ob-
tained at the moment of recruitment with previous exami-
nations, since the follow up module was not consistently
used, we needed to account for the fact that small dis-
placements of the foveal scan could occur at each visit.
Thus, for each follow up visit, we selected the highest
quality horizontal OCT scan across the fovea and used
each of the selected scans as a reference for a new acquisi-
tion at the time of the study, using the progression tool of
the Heidelberg Eye Explorer (HEYEX) software.
EZ line measures were taken manually in a masked
fashion using the calliper of the HEYEX software by two
experienced OCT-readers as shown in Fig. 1 and the
values from the two graders were averaged. EZ limit was
considered where the hyperreflective band decline to
zero. For the purpose of the study horizontal scans were
analyzed: limits were nasal and temporal to the fovea.
Also, the presence/absence of cystoid macular edema
(CME) and epiretinal membrane (ERM) was recorded.
CME was defined as the presence of hypo-reflective
spaces visible on at least two consecutive scans. ERM was
defined as the presence of a hyper-reflective line adherent
to the inner retina often together with underlying waves
in the retinal surface layer due to tractional forces.
All scans were performed with dilated pupils (using
1% tropicamide).
Only OCT scans of good quality (higher than 25 dB)
were used for the measurements.
Statistical analysis
Scans were retrieved in anonymized form from our
Spectralis database. As explained in the previous section,
in the final dataset, each patient had many progression
rate measurements derived from the difference in the
EZ line width measured from the study visit and from
each of the past sections taken as reference, divided by
the elapsed time (in years). Under the assumption that
the progression rate (but not the EZ line width) could be
considered homogeneous for slight displacements, these
measurements allowed estimation of the progression
rate across multiple follow up visits.
Calculations were performed using generalized linear
mixed models. For the progression rate of the EZ line
width, we studied the correlation of the progression
rates and the EZ line width at each baseline scan. Nested
random effects were used to obtain a multilevel model
of the error distribution to account for clustered obser-
vations within the same subject and the same family.
Specifically, the innermost grouping factor was the sin-
gle eye: this was used to account for repeated measures
performed on the same eye, allowing the calculation of a
separate mean rate for each eye considered. The second
grouping factor was the single subject: this factor
accounted for the correlation between the two eyes. Fi-
nally, family was the outermost grouping factor. The last
two random effects were used to calculate intraclass cor-
relation coefficients (ICCs) within the same family or
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subject, in order to assess how family clustering could
affect the rate of progression. The ICCs were calculated




σ2Family þ σ2Subject þ σ2Eye þ ε2
 
where the numerator is the variance attributed to the
grouping factor analyzed, while the denominator is the
total variance. Group variances are denoted as σ2 while
the residual errors are denoted as ε2. The same formula
can be applied to calculate the Subject ICC.
A gamma error distribution with a log link function was
used to account for the non-constant variance of the strictly
positive value of the progression rate. Such a modelling ap-
proach also describes the variation in the rate of change as
a proportion of the EZ width in a non-linear fashion.
Similar models were used for the other quantities ana-
lyzed, changing the error distribution according to the
different variable in study.
Results
Twenty seven patients were recruited for the study (53
eyes): 9 males (33.3%) and 18 females (66.7%).
Twelve patients (44.5%) were affected by autosomal re-
cessive RP (arRP), 9 (33.3%) by autosomal dominant RP
(adRP) and 6 (22.2%) by Usher syndrome type II.
Fig. 1 EZ band measurement: EZ limit was considered where the hyperreflective band decline to zero. In a, b and e, f horizontal scan passing
through the fovea of two couples of siblings affected by RP acquired in 2010, in c, d and g, h same scan of same patients acquired 6 years later
(2016). Patient in a was 17 years old and in 2010 and 23 years old in 2016 (c). His brother (b) was 18 years old in 2010 and 24 years
old in 2016 (d). Patient in e was 14 years old and in 2010 and 20 years old in 2016 (g). His brother (f) was 20 years old in 2010 and
26 years old in 2016 (h)
Colombo et al. BMC Ophthalmology  (2018) 18:153 Page 3 of 8
Table 1 summarizes demographic data: mean age was
42.40 years (SD ±13.70) and mean follow up time was
4.84 years (range 3–7 years).
Table 2 reports genetic results of siblings included in
the study: seven out of 12 families (58%) harboured a
genetic variation probably involved in the phenotype.
For two of them (family n°5 and 9), the genetic result
was not fully informative considering that only one
genetic variant in heterozygous state was found in the
autosomal recessive gene USH2A that is therefore not
sufficient to explain the RP phenotype.
Compound heterozygous state was confirmed by seg-
regation analysis in AR families n°6, 11 and 12.
Mean baseline EZ width was 2345.7 μm, mean EZ
width at last follow up visit was 1945.4 μm.
All patients showed an EZ line width decrease, the es-
timated mean progression rate was 76.4 μm/year (4.16%
per year, p-value < 0.0001).
Figure 2 shows the relationship between the initial EZ
line width in each B-scan and the progression rate over 1
year. The correlation between repeated observations
within the same family, the same subject and the same eye
was modeled as nested random effects (see Methods). Al-
though only 4 families out of 12 included siblings with dif-
ferent sexes, we tested the effect of sex on the progression
rate. Specifically, we used a log-likelihood ratio test to
Table 1 Demographic data
Demographic Mean Standard deviation
Age at baseline (years) 42.40 ±13.70
Follow up (years) 4.84 ± 1.44
Visual Acuity (decimal) 0.675 ± 0.235
Baseline EZ width (microns) 2345.7 ±1204.3
Last follow-up visit EZ width (microns) 1945.4 ±1123.1
Table 2 Genetic results of RP patients included in the study




1 1 M 50–55 – AR – –
2 M 45–50 – AR – –
2 3 F 40–45 USH2A AR – –
4 M 35–40 USH2A AR – –
3 5 M 20–25 – – – –
6 M 25–30 – – – –
4 7 F 65–70 – AR – –
8 F 70–74 – AR – –
5 9 F 20–25 USH2A AR c.1841-2A > G –
10 F 30–35 USH2A AR c.1841-2A > G –
6 11 F 50–55 USH2A AR c.1412_1415dup; p.(Asn472Lysfs*2) c.4124C > T; p.(Ser1375Leu)
12 M 50–55 USH2A AR c.1412_1415dup; p.(Asn472Lysfs*2) c.4124C > T; p.(Ser1375Leu)
7 13 F 45–50 NR2E3 AD c.166G > A; p.(Gly56Arg) –
14 F 50–55 NR2E3 AD c.166G > A; p.(Gly56Arg) –
15 F 45–50 NR2E3 AD c.166G > A; p.(Gly56Arg) –
16 F 45–50 NR2E3 AD c.166G > A; p.(Gly56Arg) –
8 17 M 55–60 – AR – –
18 F 50–55 – AR – –
9 19 M 25–30 USH2A AR c.299del; p.(Glu767Serfs*21) –
20 F 35–40 USH2A AR c.299del; p.(Glu767Serfs*21) –
10 21 M 20–25 PRPF8 AD c.7007G > C; p.(*2336Serext*41) –
22 F 20–25 PRPF8 AD c.7007G > C; p.(*2336Serext*41) –
23 F 25–30 PRPF8 AD c.7007G > C; p.(*2336Serext*41) –
11 24 F 35–40 USH2A AR c.5776 + 1G > A c.4758 + 3787_c.6325 + 9314del
25 F 45–50 USH2A AR c.5776 + 1G > A c.4758 + 3787_c.6325 + 9314del
12 26 F 50–55 CNGB1 AR c.827_834del; p.(Ile276Thrfs*4) c.2957A > T; p.(Asn986Ile)
27 F 45–50 CNGB1 AR c.827_834del; p.(Ile276Thrfs*4) c.2957A > T; p.(Asn986Ile)
ID patient identification number, AD autosomal dominant, AR autosomal recessive
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assess whether the inclusion of a random slope in the
mixed effect model allowing a change in rate based on
subject’s sex for each family cluster provided a significant
increase in the goodness of fit. Since the contribution of
the sex was not significant (p = 0.79) we excluded this fac-
tor from the model. The curved relationship derives from
the Gamma distribution chosen to model the variance
and the log function used to link the mean rate to the pre-
dictor. The estimated mean progression rate from the
model was 76.4 ± 1.16 μm/year (Mean ± SE) with a 38% ±
0.08% rate reduction for every 10 μm EZ line width.
From the same model we calculated the ICCs of the
Family and Subject random effects to assess the contri-
bution of each grouping factor in explaining the variabil-
ity of the progression rate (Table 3). The highest ICC
(0.175) was attributable to the Subject grouping, while
the ICC was 0.089 for the Family grouping factor and
0.068 for the Eye grouping factor, suggesting that most
of the variance can be ascribed to subject differences,
with a lesser contribution from the family cluster and
the specific eye, although the values of all ICCs calcu-
lated are small in magnitude. Figure 3 depicts the vari-
ability at the family and subject level (on the log scale of
the link function). Notice the high variability of the sin-
gle subject around the estimated mean log-rate intercept
for each family.
No statistically significant correlation was found be-
tween age and EZ line width at baseline (p-value = 0.75),
even among siblings (p-value = 0.91). Similarly, no rela-
tionship was found between the progression rate of EZ
line width and the mode of inheritance of the disease
(adRP versus arRP, p-value = 0.98). Of note, Usher syn-
drome was considered in the group of arRP.
Lastly, the percentage of eyes affected by CME did not
change during the whole follow up time (33.3%). The
percentage of eyes presenting an epiretinal membrane
slightly increased (from 49 to 54.7%).
Discussion
Our study shows that in our cohort of patients the
rate of disease progression among siblings affected by
RP, evaluated by means of SD-OCT, is not
homogenous.
Clinical and genetic heterogeneity of RP is well known.
Natural course of RP could be extremely different
among patients, with period of stability that can last
years followed by a rapid decrease of visual functions
within weeks. The landscape of identified genetic modifi-
cations responsible for the disease is becoming increas-
ingly varied, with more than 60 genes involved, each
possibly carrying many different mutations [1, 5–12].
The peculiarity of our study is the intra-familiar evalu-
ation of the progression of RP.
Different methods can be used to study the progres-
sion of RP. Full field electroretinogram (ffERG) showed
its usefulness in quantitating the natural course of dis-
ease: limits of ffERG are the lower accuracy in detecting
progression in late stages of disease and the high
test-retest variability. Because of its features, ffERG is
Table 3 Interclass correlation coefficient




Fig. 2 The blue line shows the progression rate (in microns/year) of the photoreceptor length decrease at different baseline lengths (in microns).
The curved relationship is a direct consequence of the generalized linear model when displayed on the response scale. The grey band represents
the 95% point wise confidence intervals. Single observations are overlaid as semitransparent black dots
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considered to be more reliable when evaluating
long-term rather than short-term changes.
High test-retest variability also affects subjective func-
tional evaluations with perimetric tests. On one hand,
visual field test has a large dynamic range allowing pro-
gression detection even in late stages of disease. On the
other hand, both static and kinetic perimetry depend on
patient’s collaboration. Moreover, while the former is
computer-based, the latter, which is the gold standard in
routine follow up of RP patients, might be hampered by
operator’s ability and experience in performing the test.
For the purpose of our study we evaluated the pro-
gression by means of EZ changes at SD-OCT. Recently,
EZ line width has been the subject of several studies
evaluating the rate of RP progression [34–38]. The ad-
vantages of using EZ band as marker of progression are
the low test-retest variability, the accuracy in detecting
small changes and the straightforward scan acquisition
and analysis. The most important limit is that it cannot
be used in early and late stages of the disease. In late RP,
when the outer retina is completely atrophic, EZ band is
not easily detectable. Conversely, in initial RP cases,
when outer retinal atrophy does not involve the poster-
ior pole, the margins of the EZ band cannot be identified
within classical OCT scans. However, the boundaries of
this latter limitation are being progressively blurred by
the introduction of wide field imaging [39].
In general, the mean annual rate of progression is our
dataset is comparable with previous studies: the EZ line
width reduction was 4.16% per year in accordance with 4.9–
10.9% [34, 36, 38] reported in published literature. Similarly
to published data, we observed that the progression rate of
the EZ band atrophy decreases when the margins of the
atrophic retina approach the foveal region [34, 36].
When evaluating the variability of progression rate in
our cohort of patients, the highest ICC was attributable
to subject grouping: in other terms, being part of the
same family cluster, and therefore having the same gen-
etic mutations, does not imply a similar rate of progres-
sion (Family ICC = 0.089). Interestingly, we could not
find a statistically significant correlation between age
and EZ line width among siblings. In other terms, youn-
ger siblings in one family cluster could show a more ad-
vanced stage of the disease compared to older ones.
However, the lack of any statistically significant inter-
action between progression rate and mode of inheritance
in our study could be explained by the small sample size.
We also considered the percentage of eyes affected by
CME or with presence of ERM. In our cohort 33.3% of
patients presented CME in accordance with previous re-
ports (13–49%) [40–44].
Literature about ERM incidence in RP patients is con-
troversial with range varying from 1 to 64% [41, 45, 46].
In our cohort the percentage of eyes with evidence of
ERM ranged between 49% at baseline and 54.7% at the
last follow up exam considered.
Conclusions
In conclusion, as our data suggested, RP could be ex-
tremely heterogeneous even among siblings: an accurate
and sensitive method to follow the progression of the dis-
ease is fundamental for future development of clinical trials
Fig. 3 Forest plot of the random effects via BULP (Best Unbiased Linear Predictions) derived from the fitted model of the progression rate. BULP
are the best prediction of the group mean (Family or subject), given the observations, from mixed models. The estimated intercept is indicated
filled dot and numeric values are reported above each dot. Horizontal lines represent the 95% confidence intervals of the estimates. Reported
estimates refer to the intercepts on the log-link function scale of the model and are ordered based on the estimated intercept of the family.
Notice how subjects belonging to the same family show very variable estimated intercepts
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evaluating new therapeutic strategies for RP and others ret-
inal dystrophies. For this purpose, EZ line width evaluation
could be considered one of the markers of disease progres-
sion. However, the sources of variability identified in our
model had overall low ICCs. A more detailed prospective
analysis based on follow up measurements on the same lo-
cation with retinal tracking, modelling the length of the EZ
over time instead of the change in rate, might help better
characterize the actual dynamics of the progression and re-
duce the overall variability of the estimates. Furthermore
our data suggest that, due to intra-familiar variability, sib-
lings could not offer evident advantages when used as
matched controls in treatment trials.
The limitations of our study are represented by the
relatively small sample size, the retrospective nature of
the study and, as explained above, the fact that we did
not use the same section as reference for all follow up
examinations.
Prospective studies evaluating EZ band changes with
the same reference and combining other variables as con-
trol could be helpful in understanding the precise role of
family clustering in determining progression rate of RP.
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